Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Has Consensus Target Price of $38.86

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have been assigned a consensus rating of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $38.86.

Several analysts recently weighed in on AMLX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Robert W. Baird upped their target price on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 19th. Mizuho lifted their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. HC Wainwright lifted their price target on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Finally, Citigroup boosted their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd.

Amylyx Pharmaceuticals Price Performance

NASDAQ:AMLX opened at $27.20 on Friday. The firm has a market capitalization of $3.03 billion, a P/E ratio of -19.02 and a beta of -0.10. The business has a 50 day simple moving average of $30.26 and a 200 day simple moving average of $20.99. Amylyx Pharmaceuticals has a 12-month low of $10.83 and a 12-month high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Research analysts anticipate that Amylyx Pharmaceuticals will post -1.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CFO James Frates sold 10,810 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the completion of the transaction, the chief financial officer owned 233,625 shares in the company, valued at approximately $7,560,105. The trade was a 4.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Camille Bedrosian sold 10,028 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.40, for a total value of $324,907.20. Following the completion of the transaction, the insider directly owned 278,064 shares of the company’s stock, valued at approximately $9,009,273.60. The trade was a 3.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 60,374 shares of company stock worth $1,815,257 over the last 90 days. Insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AMLX. GAMMA Investing LLC raised its position in shares of Amylyx Pharmaceuticals by 163.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,139 shares of the company’s stock worth $33,000 after buying an additional 706 shares in the last quarter. KBC Group NV bought a new position in shares of Amylyx Pharmaceuticals in the first quarter valued at approximately $26,000. State of Wyoming bought a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Amylyx Pharmaceuticals by 954.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after acquiring an additional 3,493 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $157,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile